Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
|ClinicalTrials.gov Identifier: NCT00002531|
Recruitment Status : Unknown
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : February 16, 2004
Last Update Posted : September 17, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Drug: asparaginase Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin hydrochloride Drug: dexamethasone Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: mitoxantrone hydrochloride Drug: prednisolone Drug: teniposide Drug: thioguanine Drug: vincristine sulfate Drug: vindesine Procedure: allogeneic bone marrow transplantation Procedure: peripheral blood stem cell transplantation Radiation: radiation therapy||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93)|
|Study Start Date :||January 1993|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002531
|Klinikum der J.W. Goethe Universitaet|
|Frankfurt, Germany, D-60590|
|Study Chair:||Dieter Hoelzer, MD, PhD||Johann Wolfgang Goethe University Hospital|